This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

AAPA: Recent Media Coverage Misstates Facts On FDA Pain Medication Recommendations

ALEXANDRIA, Va., Jan. 29, 2013 /PRNewswire-USNewswire/ -- The American Academy of Physician Assistants found recent media coverage misstating the facts on proposed changes to U.S. Food and Drug Administration (FDA) rules for prescribing pain medications containing hydrocodone. 

In a 19-to-10 vote, the FDA's Drug Safety and Risk Management Advisory Committee recommended reclassifying hydrocodone from a Schedule III drug to a Schedule II one, rather than imposing a rule that would "ban nurse practitioners and physician assistants from prescribing the drugs," as some major news outlets erroneously reported. This reclassification would limit prescription of these medications in states where PAs and other healthcare providers are not already authorized to prescribe Schedule II drugs. Currently, PAs can prescribe Schedule II medication in all but 14 states.

"While PAs are keenly aware of the overwhelming problems caused by the misuse of prescribed drugs — including products containing hydrocodone — we also urge policymakers to be cautious when legislating policies that will limit access to pain medications for patients with legitimate clinical needs, " said James Delaney, PA-C, AAPA president. "AAPA continues to support and promote the responsible prescription of medication as part of the profession's dedication to delivering high-quality healthcare."

In 2012, AAPA recommended to Congress that a proposal to reclassify hydrocodone products from Schedule III to Schedule II be eliminated from the Prescription Drug User Fee Act and expressed concern that other legislated barriers imposed on Schedule II drugs have made it more difficult for some patients to receive or refill legitimate prescriptions. 

The recommendation by the FDA's Drug Safety and Risk Management Advisory Committee does not mean that hydrocodone products will be automatically moved to the Schedule II classification, or that the FDA will agree to implement the committee's recommendation. If approved by the FDA, the committee's recommendation would then be subject to the U.S. Department of Health and Human Services' regulatory process before implementation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs